Case presentation

A 36-year-old HIV-positive woman with a CD4 count of 13 cells/µl was admitted to the intensive care unit (ICU) at King Edward VIII Hospital, Durban, with a 3-week history of shortness of breath (New York Heart Association grade IV) which had progressively worsened 4 days prior to admission. She also had a 2-day history of pleuritic chest pain and cough. There was no past history of tuberculosis (TB) or TB contact. The medical and surgical history was non-contributory. Clinically, the patient was noted to be well nourished, with a body mass index >25 kg/m², febrile and tachypnoeic. There were no herpetic lesions on her lips or mouth. She was in severe respiratory distress and chest auscultation revealed global crepitations with increased intensity at the bases of the lungs. The cardiac and abdominal examinations were normal. The patient was alert and orientated with no features of meningism.

Arterial blood gas analysis revealed severe type I respiratory failure with a PO₂ 4.5 kpa, PCO₂ 3.5 kpa and oxygen saturation 75%. The chest radiograph showed bilateral homogeneous opacities and a ground-glass appearance. In light of these findings the patient was intubated, ventilated and started empirically on intravenous amoxicillin-clavulanic acid and gentamycin. The haemoglobin concentration was 12.3 g/dl, the white cell count 8.0×10⁹/l and the platelet count 249×10⁹/l. Electrolyte levels and renal function were normal. Liver function tests showed a decreased albumin level of 19 g/l and an increased gamma-glutaryltransferase (GGT) level of 125 IU/l. A bacterial and fungal septic screen was performed on blood, urine and endotracheal aspirate (ETA) samples. The diagnosis of PCP was confirmed by immunofluorescent testing (Axis; Shield Diagnostics Ltd, UK) on the ETA samples, which were also negative for routine bacterial pathogens and TB. Trimethoprim (TMP) 240 mg-sulphamethoxazole (SMX) 2400 mg 6-hourly intravenously and prednisone 40 mg intravenously daily were started; however, over the next few days there was no improvement in her clinical condition. Blood and ETA samples were obtained to exclude infection with atypical bacteria and viruses. She was started empirically on piperacillin-tazobactam and amikacin for suspected nosocomial sepsis. Viral studies revealed a positive HSV-1 DNA polymerase chain reaction (PCR) on the ETA and two whole-blood samples. ETA samples were negative for cytomegalovirus and respiratory syncytial virus. HSV IgM serology was negative. The patient was immediately started on acyclovir 800 mg 8-hourly intravenously approximately 1 week after the initiation of TMP-SMX and...
HSV-1 may cause tracheobronchitis or pneumonitis and is associated with significantly increased mortality in critically ill patients. It is usually due to reactivation of the virus, which occurs as a result of certain stimuli such as fever and ultraviolet light as well as immunosuppression.1,2 It is a rare cause of respiratory disease in HIV-positive individuals, the likelihood increasing with progression to AIDS; it is an even rarer cause of respiratory infection in the immunocompetent.1

There are several hypotheses regarding the pathogenesis of HSV-1 pneumonia. The virus may reach the lower respiratory tract through contiguous spread, aspiration of the oropharynx or haematogenous spread in the presence of viraemia.1 It is usually due to reactivation and not primary disease.2,3 This was consistent with the findings in our patient, in whom testing for HSV IgM was negative.

There are no pathognomonic clinical or radiological features for HSV pneumonia. A high index of clinical suspicion with appropriate laboratory testing is required for the diagnosis. Clinically, patients may present with cough, fever, dyspnoea and hypoxaemia and failure to wean off the ventilator.1,6 Chest radiographs generally demonstrate a bilateral ground-glass appearance. Pleural effusions and patchy consolidation may also be present.6 The virus may be detected by viral isolation or PCR in broncho-alveolar lavage or endotracheal aspirate specimens. However, the significance of detecting HSV in respiratory secretions remains controversial as it may represent shedding rather than active disease.1,3 Nevertheless, the presence of HSV in respiratory secretions in severely ill patients has been associated with a poor outcome and prolonged ventilation.3 The demonstration of intranuclear inclusions or Cowdry type A bodies in biopsies is highly suggestive of active infection in the lung or in other tissue specimens.1 However, performing a lung biopsy in a ventilated patient is challenging and associated with complications. Our patient could not be weaned off the ventilator, and her condition deteriorated despite appropriate antimicrobial therapy for PCP, as well as steroids which are usually beneficial in patients with severe PCP.5,6 It has been reported in the literature that the presence of HSV in blood indicates the inability of the host to limit viral replication, with dissemination occurring particularly in immunosuppressed patients.3 HSV viraemia is typically associated with interstitial pneumonia4,10 which is in keeping with that observed in our patient with two whole blood specimens being positive for HSV-1 DNA by PCR.

The paucity of literature concerning the diagnosis and management of patients who have co-infection with HSV pneumonia and PCP suggests that this condition is either rare or under-diagnosed. Considering that both HSV-1 pneumonia and PCP have similar clinical and radiological findings, we would recommend that in patients with PCP who do not respond to appropriate therapy, co-infection with HSV-1 pneumonia should be excluded. The demonstration of HSV in blood and in respiratory samples would strongly support such a diagnosis.

It is debatable whether steroid therapy exacerbated the underlying HSV pneumonia, or contributed to ventilator dependence and overall clinical deterioration in our patient. In the absence of any other data in the literature, we suggest that if co-infection is suspected an approach would be to delay steroids for 24 - 48 hours as this immunosuppressive agent may exacerbate the HSV infection. If co-infection is confirmed, acyclovir can be given before initiation of steroids. Alternatively empiric treatment with both TMP-SMX and acyclovir together with steroids can be initiated and therapy can be modified once laboratory results become available for both PCP and HSV. Laboratory results are usually available within 24 - 48 hours.

The diagnosis of HSV-1 pneumonia-PCP co-infection is rare and management is currently speculative. The optimal therapy for this dual infection remains to be determined by means of greater awareness, further research and clinical trials.

REFERENCES


